Compare TK & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TK | PCRX |
|---|---|---|
| Founded | 1973 | 2006 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 937.1M | 1.0B |
| IPO Year | 1995 | 2010 |
| Metric | TK | PCRX |
|---|---|---|
| Price | $13.22 | $22.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $30.25 |
| AVG Volume (30 Days) | 453.2K | ★ 515.7K |
| Earning Date | 05-13-2026 | 04-30-2026 |
| Dividend Yield | ★ 15.21% | N/A |
| EPS Growth | N/A | ★ 107.44 |
| EPS | N/A | ★ 0.07 |
| Revenue | N/A | ★ $541,533,000.00 |
| Revenue This Year | N/A | $6.78 |
| Revenue Next Year | N/A | $8.54 |
| P/E Ratio | ★ $13.43 | $336.79 |
| Revenue Growth | N/A | ★ 26.04 |
| 52 Week Low | $7.12 | $18.80 |
| 52 Week High | $14.38 | $27.64 |
| Indicator | TK | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 51.19 | 41.55 |
| Support Level | $12.09 | $22.13 |
| Resistance Level | $13.76 | $24.20 |
| Average True Range (ATR) | 0.49 | 1.26 |
| MACD | -0.09 | -0.25 |
| Stochastic Oscillator | 21.85 | 8.81 |
Teekay Corp Ltd provides international crude oil marine transportation and other marine services. It also offers offshore oil production, storage, and offloading services, under long-term, fixed-rate contracts. The company has two primary lines of business: Marine services and tankers. It manages these businesses for the benefit of all stakeholders. The company serves energy and utility companies, oil traders, large oil and LNG consumers, petroleum product producers, government agencies, and various other entities that depend upon marine transportation.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.